Nektar Therapeutics (NKTR) Stock Rating Reaffirmed by Mizuho

Mizuho restated their buy rating on shares of Nektar Therapeutics (NASDAQ:NKTR) in a research report report published on Wednesday. Mizuho currently has a $89.00 price objective on the biopharmaceutical company’s stock.

“We expect both Nektar and BMY to jointly report clinical data going forward.”,” Mizuho’s analyst wrote.

Other equities research analysts also recently issued reports about the company. Canaccord Genuity Group lifted their target price on Nektar Therapeutics from $35.00 to $50.00 and gave the stock a buy rating in a research report on Wednesday, November 15th. Canaccord Genuity lifted their price objective on Nektar Therapeutics from $35.00 to $50.00 and gave the company a buy rating in a report on Monday, November 13th. Roth Capital set a $45.00 price objective on Nektar Therapeutics and gave the company a buy rating in a report on Monday, November 13th. JPMorgan Chase & Co. reaffirmed a buy rating and set a $44.00 price objective on shares of Nektar Therapeutics in a report on Monday, November 13th. Finally, Jefferies Group reaffirmed a buy rating and set a $35.00 price objective on shares of Nektar Therapeutics in a report on Wednesday, November 8th. Three research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Nektar Therapeutics has an average rating of Buy and an average price target of $46.17.

Shares of Nektar Therapeutics (NKTR) opened at $84.00 on Wednesday. Nektar Therapeutics has a 1 year low of $12.50 and a 1 year high of $99.02. The firm has a market capitalization of $11,914.01, a PE ratio of -116.67 and a beta of 2.04. The company has a debt-to-equity ratio of 2.91, a quick ratio of 3.99 and a current ratio of 4.14.

In other news, CEO Howard W. Robin sold 83,333 shares of Nektar Therapeutics stock in a transaction that occurred on Wednesday, December 13th. The shares were sold at an average price of $55.69, for a total value of $4,640,814.77. Following the completion of the transaction, the chief executive officer now owns 272,768 shares in the company, valued at $15,190,449.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Christopher A. Kuebler sold 30,000 shares of Nektar Therapeutics stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $58.66, for a total transaction of $1,759,800.00. Following the completion of the transaction, the director now owns 70,500 shares of the company’s stock, valued at approximately $4,135,530. The disclosure for this sale can be found here. Insiders have sold 196,666 shares of company stock worth $12,718,923 over the last ninety days. Company insiders own 6.10% of the company’s stock.

Large investors have recently bought and sold shares of the company. Meeder Asset Management Inc. bought a new position in shares of Nektar Therapeutics in the fourth quarter valued at approximately $121,000. SeaCrest Wealth Management LLC bought a new position in shares of Nektar Therapeutics in the fourth quarter valued at approximately $200,000. Kovack Advisors Inc. bought a new position in shares of Nektar Therapeutics in the fourth quarter valued at approximately $240,000. Sicart Associates LLC bought a new position in shares of Nektar Therapeutics in the fourth quarter valued at approximately $245,000. Finally, Eqis Capital Management Inc. bought a new position in shares of Nektar Therapeutics in the fourth quarter valued at approximately $254,000. Institutional investors own 96.00% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Nektar Therapeutics (NKTR) Stock Rating Reaffirmed by Mizuho” was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.chaffeybreeze.com/2018/02/15/nektar-therapeutics-nktr-stock-rating-reaffirmed-by-mizuho.html.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply